Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds Robert Hale to board of directors

And Jeffrey Ubben resigns from the board
Valeant Robert Hale

Valeant has added Robert Hale, a partner at ValueAct Capital, to its board of directors.

Hale will be the fourth partner of ValueAct Capital, which holds approximately 4% of Valeant's outstanding stock, to serve on the Valeant board.

ValueAct Capital has been a shareholder in Valeant since 2006 and as a partner there Hale has worked closely with the board and management team since January 2011.

He said: “It's an exciting time for Valeant as the company positions itself for long-term growth and leadership in the pharmaceuticals and medical products industry.”

Meanwhile, Jeffrey Ubben, CEO and CIO of ValueAct Capital has resigned from the board.

He said: “I have had a wonderful experience serving as director of Valeant. While I no longer serve as a director, I look forward to working with Mike Pearson and the Valeant team as an interested shareholder on an on-going basis.”

Michael Pearson, chairman and CEO of Valeant, said: “We are delighted that we will continue to have board representation from ValueAct Capital.

“We have gotten to know Rob well over the past five years and are glad that he now serves as a director. Rob's strategic and financial expertise will add a valuable perspective to our board.”

Hale, prior to his current position, was principal of The Parthenon Group working at both their Boston and Mumbai offices.

27th August 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics